Epizyme Inc. (EPZM) Earns “Outperform” Rating from Leerink Swann
A number of other equities analysts have also weighed in on EPZM. Zacks Investment Research upgraded shares of Epizyme from a hold rating to a buy rating and set a $12.00 price target on the stock in a report on Monday, July 11th. Cowen and Company restated a buy rating on shares of Epizyme in a report on Monday, June 20th. Royal Bank Of Canada restated an outperform rating and set a $26.00 target price on shares of Epizyme in a report on Monday, June 20th. HC Wainwright restated a buy rating on shares of Epizyme in a report on Monday, June 20th. Finally, Mizuho restated a buy rating and set a $18.00 target price on shares of Epizyme in a report on Monday, June 20th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $23.11.
Shares of Epizyme (NASDAQ:EPZM) traded down 1.79% during mid-day trading on Friday, reaching $9.35. The company’s stock had a trading volume of 136,731 shares. The stock’s market capitalization is $541.89 million. The company’s 50-day moving average is $8.70 and its 200-day moving average is $10.14. Epizyme has a 52 week low of $7.02 and a 52 week high of $18.29.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.03. Epizyme had a negative net margin of 5,174.49% and a negative return on equity of 43.05%. Equities analysts predict that Epizyme will post ($2.20) EPS for the current year.
In other news, insider Robert A. Copeland sold 4,000 shares of the business’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $10.37, for a total value of $41,480.00. Following the completion of the sale, the insider now owns 35,538 shares of the company’s stock, valued at approximately $368,529.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 25.40% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the company. Capital Fund Management S.A. bought a new stake in Epizyme during the second quarter valued at $398,000. Alps Advisors Inc. acquired a new position in Epizyme during the second quarter valued at approximately $823,000. American Century Companies Inc. acquired a new position in Epizyme during the second quarter valued at approximately $518,000. Candriam Luxembourg S.C.A. raised its position in Epizyme by 15.0% in the second quarter. Candriam Luxembourg S.C.A. now owns 184,000 shares of the biopharmaceutical company’s stock valued at $1,884,000 after buying an additional 24,000 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its position in Epizyme by 50.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 31,085 shares of the biopharmaceutical company’s stock valued at $377,000 after buying an additional 10,491 shares during the period. 80.79% of the stock is owned by institutional investors.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.